PPARδ: A dagger in the heart of the metabolic syndrome

Journal of Clinical Investigation

Volumn 116, Issue 3, 2006, Pages 590-597

  Barish, Grant D ^a,b   Narkar, Vihang A ^a   Evans, Ronald M ^a,c  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Gene Expression Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CARBACYCLIN; CELL NUCLEUS RECEPTOR; EZETIMIBE; FATTY ACID; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GW 0742; GW 501516; ILOPROST; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ATHEROSCLEROSIS; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HEART MUSCLE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; LIPOPROTEIN METABOLISM; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PHYSICAL STRESS; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; WEIGHT GAIN;

ANIMALS; HUMANS; LIPID METABOLISM; METABOLIC SYNDROME X; MUSCLE, SKELETAL; MYOCARDIUM; PPAR DELTA;

EID: 33644645013     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27955     Document Type: Review

References (88)

1. Flegal, K.M., Carroll, M.D., Ogden, C.L., and Johnson, C.L. 2002. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 288:1723-1727.
2. Ford, E.S. 2005. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 28:1769-1778.
3. Olshansky, S.J., et al. 2005. A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 352:1138-1145.
4. Eckel, R.H., Grundy, S.M., and Zimmet, P.Z. 2005. The metabolic syndrome. Lancet. 365:1415-1428.
5. Grundy, S.M. 2005. Point: the metabolic syndrome still lives. Clin. Chem. 51:1352-1354.
6. Perseghin, G., et al. 1999. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 48:1600-1606.
7. Kershaw, E.E., and Flier, J.S. 2004. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89:2548-2556.
8. Glass, C.K., and Witztum, J.L. 2001. Atherosclerosis: the road ahead. Cell. 104:503-516.
9. Grundy, S.M., et al. 2005. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation. 112:e285-e290.
10. Ordentlich, P., Downes, M., and Evans, R.M. 2001. Corepressors and nuclear hormone receptor function. Curr. Top. Microbiol. Immunol. 254:101-116.
11. Jepsen, K., and Rosenfeld, M.G. 2002. Biological roles and mechanistic actions of co-repressor complexes. J. Cell Sci. 115:689-698.
12. Privalsky, M.L. 2004. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu. Rev. Physiol. 66:315-360.
13. Lee, C.H., et al. 2003. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science. 302:453-457.
14. Pascual, G., et al. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 437:759-763.
15. Issemann, I., and Green, S. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:645-650.
16. Lehmann, J.M., et al. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:12953-12956.
17. Forman, B.M., et al. 1995. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 83:803-812.
18. Schmidt, A., et al. 1992. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. 6:1634-1641.
19. Dreyer, C., et al. 1992. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 68:879-887.
20. Kliewer, S.A., et al. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U. S. A. 91:7355-7359.
21. Barak, Y., et al. 2002. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 99:303-308.
22. Peters, J.M., et al. 2000. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor beta(delta). Mol. Cell. Biol. 20:5119-5128.
23. Tan, N.S., et al. 2001. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 15:3263-3277.
24. Xu, H.E., et al. 1999. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell. 3:397-403.
25. Takada, I., et al. 2000. Alteration of a single amino acid in peroxisome proliferator-activated receptor-alpha (PPAR alpha) generates a PPAR delta phenotype. Mol. Endocrinol. 14:733-740.
26. Forman, B.M., Chen, J., and Evans, R.M. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U. S. A. 94:4312-4317.
27. Yu, K., et al. 1995. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270:23975-23983.
28. Krey, G., et al. 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11:779-791.
29. Chawla, A., et al. 2003. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100:1268-1273.
30. Miller, N.E., Thelle, D.S., Forde, O.H., and Mjos, O.D. 1977. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1:965-968.
31. Wilson, P.W., Abbott, R.D., and Castelli, W.P. 1988. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 8:737-741.
32. Benoit, P., et al. 1999. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation. 99:105-110.
33. Oliver, W.R., Jr., et al. 2001. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98:5306-5311.
34. Leibowitz, M.D., et al. 2000. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett. 473:333-336.
35. van der Veen, J.N., et al. 2005. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 46:526-534.
36. Carr, D.B., et al. 2004. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 53:2087-2094.
37. [Anonymous]. 1998. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health. Obes. Res. 6(Suppl. 2):51S-209S.
38. Yanovski, S.Z., and Yanovski, J.A. 2002. Obesity. N. Engl. J. Med. 346:591-602.
39. Wang, Y.X., et al. 2003. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 113:159-170.
40. Tanaka, T., et al. 2003. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100:15924-15929.
41. Pette, D., and Staron, R.S. 2000. Myosin isoforms, muscle fiber types, and transitions. Microsc. Res. Tech. 50:500-509.
42. He, J., Watkins, S., and Kelley, D.E. 2001. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes. 50:817-823.
43. Mercier, J., Perez-Martin, A., Bigard, X., and Ventura, R. 1999. Muscle plasticity and metabolism: effects of exercise and chronic diseases. Mol. Aspects Med. 20:319-373.
44. McCullagh, K.J., et al. 2004. NFAT is a nerve activity sensor in skeletal muscle and controls activity-dependent myosin switching. Proc. Natl. Acad. Sci. U. S. A. 101:10590-10595.
45. Kamei, Y., et al. 2004. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J. Biol. Chem. 279:41114-41123.
46. Hughes, S.M., Chi, M.M., Lowry, O.H., and Gundersen, K. 1999. Myogenin induces a shift of enzyme activity from glycolytic to oxidative metabolism in muscles of transgenic mice. J. Cell Biol. 145:633-642.
47. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 137:354-366.
48. Wang, Y.X., et al. 2004. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2:e294.
49. Luquet, S., et al. 2003. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. 17:2299-2301.
50. Abbot, E.L., et al. 2005. Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. FEBS J. 272:3004-3014.
51. Solanes, G., Pedraza, N., Iglesias, R., Giralt, M., and Villarroya, F. 2003. Functional relationship between MyoD and peroxisome proliferator-activated receptor-dependent regulatory pathways in the control of the human uncoupling protein-3 gene transcription. Mol. Endocrinol. 17:1944-1958.
52. Hickey, M.S., et al. 1995. Skeletal muscle fiber composition is related to adiposity and in vitro glucose transport rate in humans. Am. J. Physiol. 268:E453-E457.
53. Higashiura, K., et al. 1999. Alteration of muscle fiber composition linking to insulin resistance and hypertension in fructose-fed rats. Am. J. Hypertens. 12:596-602.
54. Kriketos, A.D., et al. 1996. Interrelationships between muscle morphology, insulin action, and adiposity. Am. J. Physiol. 270:R1332-R1339.
55. Kelley, D.E., Goodpaster, B., Wing, R.R., and Simoneau, J.A. 1999. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am. J. Physiol. 277:E1130-E1141.
56. Manco, M., et al. 2000. Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides. Metabolism. 49:220-224.
57. Kramer, D.K., et al. 2005. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. Diabetes. 54:1157-1163.
58. Watt, M.J., Southgate, R.J., Holmes, A.G., and Febbraio, M.A. 2004. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes. J. Mol. Endocrinol. 33:533-544.
59. Mahoney, D.J., Parise, G., Melov, S., Safdar, A., and Tarnopolsky, M.A. 2005. Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise. FASEB J. 19:1498-1500.
60. Holst, D., et al. 2003. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim. Biophys. Acta. 1633:43-50.
61. Lazennec, G., Canaple, L., Saugy, D., and Wahli, W. 2000. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol. Endocrinol. 14:1962-1975.
62. Hansen, J.B., et al. 2001. Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J. Biol. Chem. 276:3175-3182.
63. Gelman, L., Michalik, L., Desvergne, B., and Wahli, W. 2005. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Curr. Opin. Cell Biol. 17:216-222.
64. Long, Y.C., Widegren, U., and Zierath, J.R. 2004. Exercise-induced mitogen-activated protein kinase signalling in skeletal muscle. Proc. Nutr. Soc. 63:227-232.
65. Coffey, V.G., et al. 2005. Early signaling responses to divergent exercise stimuli in skeletal muscle from well-trained humans. FASEB J. 20:190-192.
66. Chin, E.R. 2005. Role of Ca2+/calmodulin-dependent kinases in skeletal muscle plasticity. J. Appl. Physiol. 99:414-423.
67. Stanley, W.C., Recchia, F.A., and Lopaschuk, G.D. 2005. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85:1093-1129.
68. Cheng, L., et al. 2004. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10:1245-1250.
69. Cheng, L., et al. 2004. Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem. Biophys. Res. Commun. 313:277-286.
70. Planavila, A., et al. 2005. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc. Res. 65:832-841.
71. Planavila, A., Laguna, J.C., and Vazquez-Carrera, M. 2005. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J. Biol. Chem. 280:17464-17471.
72. Feingold, K., Kim, M.S., Shigenaga, J., Moser, A., and Grunfeld, C. 2004. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am. J. Physiol. Endocrinol. Metab. 286:E201-E207.
73. Vosper, H., et al. 2001. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J. Biol. Chem. 276:44258-44265.
74. Li, A.C., et al. 2004. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J. Clin. Invest. 114:1564-1576. doi:10.1172/JCI200418730.
75. Welch, J.S., Ricote, M., Akiyama, T.E., Gonzalez, F.J., and Glass, C.K. 2003. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100:6712-6717.
76. Graham, T.L., et al. 2005. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis. 181:29-37.
77. Lee, C.H., et al. 2006. PPAR delta is a potent insulin sensitizer. Proc. Natl. Acad. Sci. U. S. A. In press.
78. He, T.C., Chan, T.A., Vogelstein, B., and Kinzler, K.W. 1999. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 99:335-345.
79. Reed, K.R., et al. 2004. PPARdelta status and Apcmediated tumourigenesis in the mouse intestine. Oncogene. 23:8992-8996.
80. Harman, F.S., et al. 2004. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat. Med. 10:481-483.
81. Gupta, R.A., et al. 2004. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat. Med. 10:245-247.
82. Park, B.H., Vogelstein, B., and Kinzler, K.W. 2001. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc. Natl. Acad. Sci. U. S. A. 98:2598-2603.
83. Saez, E., et al. 1998. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med. 4:1058-1061.
84. Lefebvre, A.M., et al. 1998. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4:1053-1057.
85. Schoeller, D.A. 2001. The importance of clinical research: the role of thermogenesis in human obesity. Am. J. Clin. Nutr. 73:511-516.
86. Lakka, T.A., et al. 2003. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med. Sci. Sports Exerc. 35:1279-1286.
87. Bishop-Bailey, D., and Hla, T. 1999. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12,14-prostaglandin J2. J. Biol. Chem. 274:17042-17048.
88. Zhang, J., et al. 2002. Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J. Biol. Chem. 277:11505-11512.